Quetiapine extended release: Adjunctive treatment in major depressive disorder

CNS Drugs

Volumn 25, Issue 9, 2011, Pages 803-813

  Sanford, Mark ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Major depressive disorder; Quetiapine

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; CARBAMAZEPINE; CIMETIDINE; CITALOPRAM; CLARITHROMYCIN; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; ESCITALOPRAM; FLUOXETINE; HALOPERIDOL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; IMIPRAMINE; KETOCONAZOLE; LEVODOPA; LITHIUM; NEFAZODONE; PAROXETINE; PHENAZONE; PHENYTOIN; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; VALPROATE SEMISODIUM; VENLAFAXINE;

AGRANULOCYTOSIS; AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; BLOOD DYSCRASIA; CONSTIPATION; DISEASE COURSE; DISEASE SEVERITY; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENDED DRUG RELEASE; FATIGUE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT PROLONGATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SUSTAINED DRUG RELEASE; TARDIVE DYSKINESIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052145818     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11207280-000000000-00000     Document Type: Article

References (25)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun 18; 289 (23): 3095-105 (Pubitemid 37432885)
2. World Health Organization. The global burden of disease: 2004 update [online]. Available from URL: http://www.who.int/healthinfo/global-burden- disease/GBD-re port-2004update-full.pdf [Accessed 2011 Mar 7]
3. Janicak PG, Dowd SM. Treatment-resistant depression: an update on diagnosis and management. Psychopharm Rev 2009; 44 (6): 41-8
4. Mann JJ. The medical management of depression. N Engl J Med 2005; 353 (17): 1819-34
5. Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010; 71 Suppl. E1: e04
6. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009 Sep; 166 (9): 980-91
7. European Medicines Agency. Questions and answers on Seroquel XR and associated names (50, 150, 200, 300 and 400 mg prolonged-release tablets containing quetiapine): outcome of a procedure under Article 6(13) of Regulation (EC) 1084/2003 as amended. Available from URL: http://www.ema.europa.eu/docs/ en-GB/document-library/Refer rals-document/Seroquel-XR-6/WC500089663.pdf [Accessed 2010 Jul 14]
8. The electronic Medicines Compendium (eMC). Seroquel XR 50 mg, 150 mg, 200mg, 300 mg, 400mg prolonged-release tablets: summary of product characteristics [online]. Available fromURL: http://www.medicines.org.uk/emc/ document.aspx? documentid=21175&docType=SPC [Accessed 2011 Feb 8]
9. AstraZeneca. Seroquel XR (quetiapine fumarate) tablets: prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/02204 7s023s027tbl.pdf [Accessed 2011 Jul 21]
10. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007 Jun; 8 (9): 1211-9 (Pubitemid 47034411)
11. Nyberg S, Widzowski D. Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties [abstract no. PW01-27]. Eur Psychiatry 2010; 25 Suppl. 1: 1446
12. Jensen NH, Rodriguiz RM, Caron MG, et al. Ndesalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacol 2008 Sep; 33 (10): 2303-12
13. Nyberg S, Takano A, Jucaite A, et al. PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects [abstract no. P.1.e.019]. Eur Neuropsychopharmacol 2008; 18 Suppl. 4: S270
14. Datto C, Berggren L, Patel JB, et al. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009 Mar; 31 (3): 492-502
15. Nord M, Nyberg S, Brogren J, et al. Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extendedrelease formulations in healthy subjects. Int J Neuropsychopharmacol. Epub 2011 Apr 11
16. MamoDC,UchidaH,Vitcu I, et al.Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008; 69 (1): 81-6 (Pubitemid 351282000)
17. Gedge L, Lazowski L, Murray D, et al. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. Neuropsychiatric Dis Treat 2010; 6 (1): 501-8
18. De Vane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40 (7): 509-22
19. Wang J-S, Zhu H-J, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 2006 Sep; 187 (4): 415-23 (Pubitemid 44200513)
20. Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009 Mar 17; 33 (2): 199-204
21. Bauer M, Pretorius HW, Constant EL, et al. Extendedrelease quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009 Apr; 70 (4): 540-9
22. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13 (7): 917-32
23. Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010 Dec; 127 (1-3): 19-30
24. Bandelow B, Bauer M, Vieta E, et al. Pooled analysis of the efficacy of adjunctive quetiapine XR in patients with major depressive disorder and high or low levels of baseline anxiety [abstract no. P06]. Int J Psychiat Clin Pract 2010; 14 Suppl. 1: 19
25. Bauer M, Dell'Osso L, Kasper S, et al. Quetiapine XR monotherapy, quetiapine XR+ ongoing antidepressants and lithium+ ongoing antidepressants in patients with treatmentresistant major depressive disorder [abstract no. p-09.004]. Int J Neuropsychopharmacol 2010; 13 Suppl. 1: 143